Hojiej et al. Prevalence and Impact of lifestyle factors in PsA. Lifestyle factors impacted disease activity. Cumulative effect of increasing number of factors @RheumNow #ACR25 Abstr#2309 https://t.co/oDGQyLBRDO

MAINRITSEG: RTX vs. AZA for maintenance in EGPA RTX not superior in primary remission outcome RTX favored in secondary outcome of remission with pred <4mg daily Limitation: only ~50% pt with FFS 1+ @RheumNow #ACR25 Abst 1765 https://t.co/dh5ZWCT12T

Girolami et al. VA study. Safety of DMARDs in RA following melanoma. 644 patients. 3 year all cause mortality. No significant difference, but graph sure looks like b/tsDMARDs are better. No melanoma specific mortality/recurrence data however. @RheumNow #ACR25 Abstr#2237 #ACRBest https://t.co/IN4LDkioT7

Is RA-ILD associated with/ higher risk of infection? Retrospective US cohort study 151 RA-ILD 980 matched controls 79% higher risk of any and pulmonary infections in RA-ILD Pathogen type: bacterial, viral and fungi Some of these infections are preventable! Take Home: https://t.co/fPmRjLL7Po

In DISCOVER-2, male PsA patients had greater radiographic progression than females despite similar baseline scores. Early joint response (W8 cDAPSA LDA) was linked to less progression more strongly in men. Highlights the sex differences in PsA outcomes. Abstract#2345 @RheumNow https://t.co/zIo59FYPVg

Macedo et al. Increasing exercise improved QoL in axSpA. Mobility limitation and obesity worsened it. At least to some degree these effects appear independent. @RheumNow #ACR25 Abstr#2326 https://t.co/Ei4cKTNHyn

A prediction model for RA-ILD in RA pts: is it possible? Not quite yet! Veterans Affairs RA registry 2700+ pts 5% of prevalent ILD Associated w/ -GDF-15 -Pentraxin 3 No prediction for Incident disease Needs more work to understand implications for practice @RheumNow #ACR25 https://t.co/CmW72nybcQ

Gender differences in p/axSpA in Turkiye from ASAS-PerSpA: Males - early onset IBP (<45yrs); sacroiliitis on CR, HLA-B27+ (vs. females) Females - peripheral dse, enthesitis, Pso, dactylitis; ⬆️dse activity, FM (vs. males) Individualize & optimize tx. #ACR25 @RheumNow Abs2322 https://t.co/vcisNguJLB

Great debate on GCA ultrasound vs biopsy. Wolfgang Schmidt making the case for GCA US with the rise of its use in guidelines @RheumNow #ACR25 https://t.co/ORxzzG8xnF

Simulation modeling by Patel et al helps generate probability of remission, relapse, and adverse events in newly dx AAV Projected risk by model were similar to observed rates in RCTs @RheumNow #ACR25 Abst 1764 https://t.co/xevkJ2Ih0M

Rotation or Change in Biologic post TNFi failure in axSpA. Switching biologic class after TNFi failure improved outcomes in axial SpA. In a randomized trial of axSpA patients with inadequate response to a first TNFi, switching to an IL-17Ai was not superior to cycling to a second https://t.co/MEsokWeT8e

This cohort study from Ontario of 🚺w/axSpA ✳️GDM, antepartum hem, SMM (severe maternal morbidity) -⬆️ in axSpA ✳️Neonat complications-preterm birth Factors assoc w/SMM- age, comorbidity, gestational age at delivery Better strategies for maternal care #ACR25 @RheumNow Abs2200 https://t.co/LrVzJLnvWe

HCQ weight-based dosing: out HCQ whole blood monitoring: in Whole blood levels more precisely balance risks of SLE flare (under-dosing) vs. toxicitiy (over-dosing) Many pt on <5 mg/kg had supra-therapeutic blood levels with risk for toxicity @RheumNow #ACR25 #ACRBest Abst 1722 https://t.co/qIbACxAW39

Mimics of ANCA-associated vasculitis: How can we tell? With increased disease awareness and more regular, accessible testing for anti-neutrophil cytoplasmic antibodies (ANCA), ANCA-associated vasculitis (AAV) has become an increasingly recognized clinical entity in rheumatologic https://t.co/LYRk0rHlzx